Håkansson, Claes http://orcid.org/0000-0002-6032-2445
Tamaddon, Ashkan
Andersson, Henrik
Torisson, Gustav
Mårtensson, Gustav
Truong, My
Annertz, Mårten
Londos, Elisabet
Björkman-Burtscher, Isabella M.
Hansson, Oskar
van Westen, Danielle
Funding for this research was provided by:
Vetenskapsrådet (2016-00906)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marianne and Marcus Wallenberg Foundation (2015.0125)
Alzheimerfonden (AF-939932)
Hjärnfonden (FO2019-0326)
Parkinsonfonden (1280/20)
Greta och Johan Kocks stiftelser
Skånes universitetssjukhus (2020-O000028)
Swedish government under the ALF agreement (2018-Projekt0279)
Strategic Research Area MultiPark at Lund University,
Regionalt forskningsstöd (2020-0314)
Article History
Received: 8 January 2021
Revised: 3 June 2021
Accepted: 25 June 2021
First Online: 30 July 2021
Declarations
:
: The scientific guarantor of this publication is Danielle van Westen.
: The authors of this manuscript declare relationships with the following companies: OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. The other authors declare no conflicts of interest.
: One of the authors has significant statistical expertise.
: Written informed consent has been obtained from all subjects included in the BioFINDER study. Additional written informed consent was waived by the Institutional Review Board for this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in Håkansson et al <i>Neurology</i> 2019; 61:397-404, and Håkansson et al <i>Eur Radiol</i> 2021; 31:666-673.
: • Retrospective• Observational• Performed at one institution